Related Experiment Video
Updated: Jun 22, 2026

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
Published on: February 23, 2024
Personalized medicine: a perk of privilege?
1Division of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA. jengrigg@umich.edu
Abstract:
Advances in molecular testing and genomic technology offer promise in helping identify people at risk of developing disease and those most (or least) likely to benefit from risk reduction and treatment strategies. Yet not all of those who are eligible for such technologies have access to the benefits of these advances. Given the inequities in our health-care system, there is no assurance that expanding research into molecular and genomic testing will benefit everyone equally. Moreover, widespread adoption of new and emerging technologies poses challenges for an already overtaxed health-care system.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Dosage Regimen: Individualization
Principles of Pharmacogenetics: Types of Genetic Variants

